Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clemastine and Aerobic Exercise for Cognitive Dysfunction in Schizophrenia
DRKS00032316Phase 2Recruiting
- Sponsor
- LMU Klinikum
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Add-on clemastine + aerobic exercise training with Add-on placebo + aerobic exercise training (2 arms). Started Jul 2023; status: recruiting.
02
Drugs
clemastine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on DRKS00032316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00032316.